A New Analysis Relating To Education


One killed in traffic collision in Castaic One person was killed and three others were critically injured in a four-vehicle traffic collision on the northbound side of Interstate 5 in Castaic Friday morning. The Los Angeles County Fire Department received a call regarding a two-vehicle traffic collision near Templin Highway shortly before 3 a.m., but when first responders arrived on the scene they discovered four vehicles were involved, according to Supervisor Bernard Peters with L.A. County Fire. “There were four vehicles found at the scene and three critical patients,” Peters said. “One patient was (dead on arrival).” Peters added one person sustained minor injuries as a result of the collision. A SigAlert was issued by California Highway Patrol shortly after the crash, according to a CHP incident log. Three lanes were shut down for about four hours and the SigAlert was canceled at 7:30 a.m. This is a breaking news story and information will be updated when available.


[Education] [Traffic]

That’s important, she says, because stopping viral replication in the nose can reduce the spread of infection among people who may be unaware anonymous they are sick. But she cautions that monkeys are not people. “We can’t really conclude that this vaccine is going to be better in practice until we have some reliable safety and efficacy data in people.” That’s why researchers will be eager to see results from Novavax’s phase III trials. In the one in progress in the United Kingdom, volunteers get either placebo or vaccine in two injections, 21 days apart. Researchers will evaluate whether vaccinated volunteers have fewer symptomatic coronavirus infections than placebo recipients. They’ll also keep monitoring safety, including any reactions to the adjuvant, because this will be the first time huge numbers of younger people with vigorous immune systems receive it. Vaccine trials need volunteers who are exposed to the virus, so skyrocketing infections in the United Kingdom are likely working in Novavax’s favor. The company estimates there will be enough infections among participants to allow a first look at the data early in 2021—and says it expects the U.K. data will be enough to drive approval of its vaccine.